The DEA has proposed moving three insomnia drugs down a schedule, and the proposal states that the schedule they are leaving and the one they are joining carry identical controls
A drug moving down a schedule sounds like a loosening. Read the proposal and it is not one.
The Drug Enforcement Administration filed a notice of proposed rulemaking on Monday to transfer three prescription insomnia drugs, suvorexant, lemborexant and daridorexant, from schedule IV of the Controlled Substances Act into schedule V. The three are selective dual orexin receptor antagonists, and the notice says they are the only three substances with that exact mechanism of action. It reaches the Federal Register on Tuesday.
Then comes the sentence the rest of the document has to be read against. "Under the CSA, schedule IV and V controlled substances are subject to identical regulatory controls and administrative sanctions."
The ten requirements do not move
The notice sets out what would apply to anyone handling the three drugs once they sit in schedule V, and it runs to ten headings: registration with DEA, disposal of stocks by anyone unwilling or unable to keep a registration, security and employee screening, labelling and packaging, inventory, records and reports, prescriptions, manufacturing and distributing, importation and exportation, and liability for any activity the statute does not authorise.
Having listed them, the notice says the transfer would impose the same controls and sanctions as those that currently exist.
Three of those headings carry the same carve-out, in the same words each time. Registration, security and inventory do not apply to patients who possess the drugs under a lawful prescription. That was already true in schedule IV.
What the record actually holds
The counts are small and the document gives them by drug. Suvorexant, approved first and on the market longest, accounted for 674 cases in America's Poison Centers National Poison Data System and 154 in the FDA Adverse Event Reporting System. Lemborexant accounted for 217 and 15. Daridorexant, which the notice describes as the one with the least marketed time, accounted for 66 and 35. HHS identified 17 emergency department visits involving one of the three.
Law enforcement encounters are smaller again. Across the eleven years from 2015 to December 2025, the National Forensic Laboratory Information System registered 53 reports for suvorexant and one apiece for lemborexant and daridorexant, from 22 states. DEA writes that those encounters indicate the substances are being trafficked and distributed in the United States. The same section records that FDA is not aware of any significant diversion from legitimate drug channels, including from research activities or manufacturing facilities.
On abuse potential the evidence points two ways and the notice says so. Human abuse potential studies produced subjective effects similar to schedule IV substances such as zolpidem. The counts of abuse and misuse were lower than for zolpidem and temazepam, and HHS said that gap may be attributable, at least in part, to lower overall use of the newer drugs.
Twenty two months at HHS
The timeline is in the document. DEA gathered the necessary data and sent it to the then-Assistant Secretary for Health on 14 February 2024, asking for a scientific and medical evaluation and a scheduling determination. HHS came back on 31 December 2025 with an evaluation and a recommendation to move all three to schedule V. That is 22 months between the request and the answer, and another seven months before the proposal was filed.
The three drugs entered schedule IV years apart, as each was approved: suvorexant in August 2014, lemborexant in March 2021, daridorexant in September 2022.
One last line is worth noting for what it forecloses. Scheduling actions run as formal rulemaking on the record under 5 U.S.C. 556 and 557, they are exempt from review by the Office of Management and Budget, and the notice states expressly that DEA scheduling actions are not subject to Executive Order 14192 on deregulation or Executive Order 14294 on overcriminalisation. A move down the schedules is not being counted as either.
Comments and hearing requests close 30 days after publication, which is 10 September 2026.
